ABCL Q3 2024 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M-1.4% YoY

Gross Profit

$7M100.0% margin

Operating Income

-$94M-1439.4% margin

Net Income

-$51M-785.4% margin

EPS (Diluted)

$-0.17

QoQ Revenue Growth

-11.1%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$48M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$315M

Stockholders' Equity

$1.1B

Cash & Equivalents

$127M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$7M	-1.4%
Gross Profit	$7M	$7M	-1.4%
Operating Income	-$94M	-$55M	-70.6%
Net Income	-$51M	-$29M	-78.6%

Revenue Segments

Research Fees

$6M97%

License

$218,0003%